Needham & Company LLC Cuts Artivion (NYSE:AORT) Price Target to $32.00

Artivion (NYSE:AORT) had its target price decreased by Needham & Company LLC from $34.00 to $32.00 in a research note issued to investors on Tuesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

AORT has been the topic of a number of other reports. Oppenheimer boosted their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion has a consensus rating of “Buy” and an average price target of $31.40.

Artivion Stock Down 0.2 %

Artivion stock opened at $25.38 on Tuesday. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -1,268.85 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $29.63 and its two-hundred day moving average price is $27.81. Artivion has a 52 week low of $18.38 and a 52 week high of $32.33.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. On average, analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity

In other news, CFO Lance A. Berry sold 3,259 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $89,003.29. Following the sale, the chief financial officer now owns 75,805 shares in the company, valued at $2,070,234.55. The trade was a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John E. Davis sold 6,457 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $176,340.67. Following the sale, the insider now owns 160,631 shares in the company, valued at $4,386,832.61. This represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 77,224 shares of company stock worth $2,162,330 over the last 90 days. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC grew its position in Artivion by 30.8% during the fourth quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock valued at $1,021,000 after purchasing an additional 8,404 shares in the last quarter. Tidal Investments LLC grew its position in Artivion by 14.5% during the fourth quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock valued at $5,141,000 after purchasing an additional 22,804 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Artivion during the fourth quarter valued at approximately $64,000. Point72 Asset Management L.P. purchased a new position in Artivion during the fourth quarter valued at approximately $5,573,000. Finally, ProShare Advisors LLC grew its position in Artivion by 44.7% during the fourth quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock valued at $341,000 after purchasing an additional 3,683 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.